Peter Pisters is one of the top 10 CEOs, according to Glassdoor. Photo courtesy of MD Anderson

Three Houston-area CEOs are doing a exemplary job of leading, says a new report.

Dr. Peter Pisters (MD Anderson Cancer Center), Dr. Marc Boom (Houston Methodist), and Worthing Jackman (Waste Connections) appear on Glassdoor's new list of the top 100 CEOs for 2021.

Pisters scored particularly well; he ranked third overall on the prestigious list and earned a 99-percent approval rating from MD Anderson employees who shared anonymous feedback on the Glassdoor platform, which publishes reviews and salary information for employers.

Meanwhile, Boom ranked 60 overall with a 93 percent approval, while Jackman came in at 76 overall with a 92 percent approval.

Other Texas executives appearing on the new Glassdoor list are:

  • Seventh-ranked Charles Butt, CEO of San Antonio-based H-E-B (96 percent).
  • Fourth-ranked Gary Kelly, who just announced he's stepping down as CEO of Dallas-based Southwest Airlines (98 percent approval).
  • 55th-ranked Sean Yalamanchi, chairman and president of Richardson-based Infovision (93 percent approval).

"Over the past year, company leaders around the world faced unprecedented challenges to support employees during the COVID-19 crisis. Now, the employees have spoken and it's clear that these CEOs excelled and found new ways to support their people when the world of work flipped upside down," Christian Sutherland-Wong, Glassdoor's CEO, says in a news release.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.